Turin, Italy

Mauro Papotti

This inventor holds 1 USPTO granted patent. Top assignee: Asta Medica, Aktiengesellschaft. Active years: 2000.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mauro Papotti: Innovator in Tumor Treatment

Introduction

Mauro Papotti is a notable inventor based in Turin, Italy. He has made significant contributions to the field of medicine, particularly in the treatment of tumors. His innovative approach focuses on utilizing growth hormone-releasing compounds to combat tumorigenic cells.

Latest Patents

Mauro Papotti holds a patent for a method titled "Treatment of tumors by administration of growth hormone releasing." This patent describes a method for treating tumors in mammals by administering a growth hormone-releasing compound or an antagonist thereof. The treatment aims to reduce or inhibit the proliferation of tumorigenic cells, specifically targeting tumors such as lung, mammary, thyroid, or pancreas tumors. The preferred compounds in this method include certain peptides that contain methyl tryptophan and lysine units. He has 1 patent to his name.

Career Highlights

Mauro Papotti is associated with Asta Medica, Aktiengesellschaft, where he continues to work on innovative medical solutions. His research and development efforts have positioned him as a key figure in the medical community, particularly in oncology.

Collaborations

Mauro has collaborated with esteemed colleagues such as Gianpiero Muccioli and Ezio Ghigo. Their combined expertise has contributed to advancements in tumor treatment methodologies.

Conclusion

Mauro Papotti's work in the field of tumor treatment exemplifies the impact of innovative thinking in medicine. His patent and ongoing research continue to pave the way for new therapeutic approaches.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…